Crossmark

Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA

Crossref DOI link: https://doi.org/10.1007/s13410-018-0657-7

Published Online: 2018-06-12

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mitkova, Zornitsa

Mitov, Konstantin

Valov, Vasil

Manova, Manoela

Savova, Alexandra

Kamusheva, Maria

Tcharaktchiev, Dimitar

Angelov, Zhivko

Angelova, Galia

Petrova, Guenka
License Information

Text and Data Mining valid from 2018-06-12
More Information

Article History

Received: 23 March 2018

Accepted: 4 June 2018

First Online: 12 June 2018